Epigenetic modulation enhances the therapeutic effect of anti-IL-13Ra2 antibody in human mesothelioma xenografts

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2819-2829

  Takenouchi, Makoto ^a,b   Hirai, Sachie ^c   Sakuragi, Naoya ^c   Yagita, Hideo ^a   Hamada, Hirofumi ^c   Kato, Kazunori ^a,c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAMMA INTERFERON; INTERLEUKIN 13 RECEPTOR ALPHA2 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURFACE; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MONITORING; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; EPIGENESIS, GENETIC; FEMALE; HCT116 CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, KNOCKOUT; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955510603     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2986     Document Type: Article

References (37)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
3. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12:5777-85. (Pubitemid 44629609)
4. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC, et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005;99:135-41. (Pubitemid 41354594)
5. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-a by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001;61:7025-9. (Pubitemid 32946489)
6. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, et al. De novo induction of a cancer/testis antigen by 5-aza-20-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006;66:1105-13. (Pubitemid 43165979)
7. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13a2 receptor is involved in induction of TGFb1 production and fibrosis. Nat Med 2006;12:99-106. (Pubitemid 43050083)
8. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, et al. Restoration of tumor immunosurveillance via targeting of interleukin- 13 receptor-a2. Cancer Res 2008;68:3467-75.
9. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor a2 in pancreatic cancer invasion and metastasis. Cancer Res 2009;69:8678-85.
10. Bernard J, Treton D, Vermot-Desroches C, Boden C, Horellou P, Angevin E, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ra2 as a decoy receptor for IL13. Lab Invest 2001;81:1223-31. (Pubitemid 32911971)
11. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor a2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2010;16: 577-86.
12. Kunwar S, Prados MD, Chag SM, Berger MS, Lang FF, Piepmeier JM, et al. Direct intracerebral delivery of Cintredekin Besudotox (IL13- PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44. (Pubitemid 350002884)
13. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010;12:871-81.
14. Kioi M, Seetharam S, Puri RK. Targeting IL-13Ra2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 2008;7:1579-87.
15. Tajima A, Tanaka T, Ebata T, Takeda K, Kawasaki A, Kelly JM, et al. Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo. J Immunol 2003;171:1715-21. (Pubitemid 36966454)
16. Suzuki K, Nakamura K, Kato K, Hamada H, Tsukamoto T. Exploration of target molecules for prostate cancer gene therapy. Prostate 2007;67:1163-73. (Pubitemid 47221884)
17. Tanaka T, Huang J, Hirai S, Kuroki M, Kuroki M, Watanabe N, et al. Carcinoembryonic antigen-targeted selective gene therapy of gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 2006;12:3803-13. (Pubitemid 44000262)
18. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using largescale transcriptional profiling. Am J Pathol 2005;166:1827-40. (Pubitemid 40734405)
19. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003;9:3080-97. (Pubitemid 36993271)
20. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006;66:2970-9.
21. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
22. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005;16:345-51. (Pubitemid 40458309)
23. Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005;19:1117-36. (Pubitemid 41736046)
24. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
25. Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009;69:227-34.
26. Christensen BC, Marsit CJ, Houseman EA, Godleski JJ, Longacker JL, Zheng S, et al. Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res 2009;69:6315-21.
27. Schrump DS, Nguyen DM. Targeting the epigenome for the treatment of thoracic malignancies. Thorac Surg Clin 2006;16:367-77. (Pubitemid 44828814)
28. Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010;5:275-9.
29. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, et al. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 2009;66:184-90.
30. Vogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997;79:2237-42.
31. Chen W, Sivaprasad U, Tabata Y, Gibson AM, Stier MT, Finkelman FD, et al. IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice. J Immunol 2009;183:7870-6.
32. Wu AH, Low WC. Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter. Neuro Oncol 2003;5:179-87. (Pubitemid 36790347)
33. Hamm CA, Xie H, Costa FF, Vanin EF, Seftor EA, Sredni ST, et al. Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-20-deoxycytidine results in increased tumorigenicity. PLoS One 2009;4:e8340.
34. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Ménard O, et al. Intrapleural infusion of activated macrophages and g-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002;121:1921-7. (Pubitemid 34634415)
35. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, et al. Intrapleural treatment with recombinant gammainterferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460-7. (Pubitemid 24320849)
36. Vivo C, Lévy F, Pilatte Y, Fleury-Feith J, Chrétien P, Monnet I, et al. Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. Oncogene 2001;20:1085-93. (Pubitemid 32238857)
37. Hiroi M, Mori K, Sekine K, Sakaeda Y, Shimada J, Ohmori Y. Mechanisms of resistance to interferon-g-mediated cell growth arrest in human oral squamous carcinoma cells. J Biol Chem 2009;284: 24869-80.